Literature DB >> 14532980

HER2 testing in gastric cancer: molecular morphology and storage time-related changes in archival samples.

Mauro Risio1, Giovanni De Rosa, Ivana Sarotto, Laura Casorzo, Lorenzo Capussotti, Bruno Torchio, Massimo Aglietta, Laura Chiecchio.   

Abstract

Seventy-two archival specimens of advanced gastric adenocarcinoma were analyzed by fluorescence in situ hybridization and immunohistochemistry for HER2 gene status. Gene amplification and concomitant protein overexpression were detected in 15.2% of cases. Intratumor topographical variability of HER2 amplification was observed, indicative of the late involvement of HER gene in gastric tumorigenesis. No significant correlations were found between HER2 status and histopathologic type, grade of differentiation, and Goseki classification of carcinomas, suggesting that HER2 gene is variably linked with the morphogenesis of gastric adenocarcinoma. A significant decrease of the incidence of HER2 amplified carcinomas in function of the duration of the storage of paraffin blocks was observed: 42-33% for tumor specimens paraffin-embedded in 2002-2001; 8.3%, 15.7%, 11.1% for the years 2000, 1999, 1998, respectively; 0% for cases embedded during 1997. According to these results, the reliability of the FISH and immunohistochemical assays decreases after prolonged storage of paraffin-embedded specimens.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14532980

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  8 in total

1.  Molecular evidence for association of chlamydiales bacteria with epitheliocystis in leafy seadragon (Phycodurus eques), silver perch (Bidyanus bidyanus), and barramundi (Lates calcarifer).

Authors:  Adam Meijer; Paul J M Roholl; Jacobus M Ossewaarde; Brian Jones; Barbara F Nowak
Journal:  Appl Environ Microbiol       Date:  2006-01       Impact factor: 4.792

2.  HER2 expression in locally advanced gastric cancer with extensive lymph node (bulky N2 or paraaortic) metastasis (JCOG1005-A trial).

Authors:  Tomohiro Matsumoto; Mitsuru Sasako; Junki Mizusawa; Seiichi Hirota; Atsushi Ochiai; Ryoji Kushima; Hitoshi Katai; Yoichi Tanaka; Norimasa Fukushima; Atsushi Nashimoto; Akira Tsuburaya
Journal:  Gastric Cancer       Date:  2014-07-04       Impact factor: 7.370

3.  HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment.

Authors:  Pamela L Kunz; Amirkaveh Mojtahed; George A Fisher; James M Ford; Daniel T Chang; Raymond R Balise; Charles D Bangs; Athena M Cherry; Reetesh K Pai
Journal:  Appl Immunohistochem Mol Morphol       Date:  2012-01

4.  Consensus of the Spanish Society of Medical Oncology (SEOM) and Spanish Society of Pathology (SEAP) for HER2 testing in gastric carcinoma.

Authors:  Carlos Gómez-Martín; Angel Concha; José María Corominas; Tomás García-Caballero; Elena García-García; Mar Iglesias; José Antonio López; Santiago Ramón y Cajal; Federico Rojo; José Palacios; Francisco Vera-Sempere; Enrique Aranda; Ramon Colomer; Pilar García-Alfonso; Pilar Garrido; Fernando Rivera; Fernando López-Ríos
Journal:  Clin Transl Oncol       Date:  2011-09       Impact factor: 3.405

5.  Human epidermal growth factor receptor-2 gene amplification in gastric cancer using tissue microarray technology.

Authors:  Dimitrios Tsapralis; Ioannis Panayiotides; George Peros; Theodore Liakakos; Eva Karamitopoulou
Journal:  World J Gastroenterol       Date:  2012-01-14       Impact factor: 5.742

6.  Signal transduction proteins in tumors from Puerto Rican and Caucasian gastric adenocarcinoma patients: expression differences with potential for specific targeted therapies.

Authors:  José Cangiano; Barbara A Centeno; Christopher R Garrett; William Cáceres; Ana de Jesús; Ji-Hyun Lee; Orestes Pavía; Richard Jove; Luis Báez; Daniel M Sullivan; Carlos A Muro-Cacho; Teresita Muñoz-Antonia
Journal:  Dig Dis Sci       Date:  2008-01-26       Impact factor: 3.199

7.  HER2 status in gastro-oesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH and SISH).

Authors:  James E Boers; Harriëtte Meeuwissen; Natalie Methorst
Journal:  Histopathology       Date:  2011-02-16       Impact factor: 5.087

8.  Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer.

Authors:  S Iqbal; B Goldman; C M Fenoglio-Preiser; H J Lenz; W Zhang; K D Danenberg; S I Shibata; C D Blanke
Journal:  Ann Oncol       Date:  2011-03-17       Impact factor: 32.976

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.